The University of Osaka · 의학
Shingo Ohira 교수의 연구실은 방사선 옹호 치료의 정밀도와 안정성을 향상시키는 데 초점을 맞추고 있습니다. 특히 하이퍼프로토닉 방사선 치료(HA-VMAT)와 HyperArc를 활용한 뇌전이성 종양 치료에서의 피부선량 최소화, 정밀한 기립 위치 보정, 그리고 MLC 설계 최적화에 대한 연구를 진행하고 있습니다. 환자 고정 장치의 정확도와 치료 시간이 이동에 미치는 영향 분석을 통해 임상 적용의 안정성도 확보하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
HA-VMAT plans provided significantly higher conformity and rapid dose falloff with respect to the C-VMAT plans.
The rotational setup errors for multiple brain metastases cases caused non-negligible underdosage for PTV and significant increases of V<sub>10Gy</sub> to V<sub>16Gy</sub> in SRS with HyperArc.
Encompass provided patient immobilization with adequate accuracy during HA treatment. The absolute maximum displacement IM was less than IM<sub>NC</sub> along the translational/rotational axes, and no statistically significant relationship between the treatment time and the IM was observed.
The narrower MLC provided significantly higher conformity, steeper dose gradient, and better normal tissue sparing.
The IME during STI using open- and full-face clamshell-style immobilization devices is approximately equal considering the adequate accuracy in patient positioning.
Our findings demonstrate the accuracy of the MC model using an adapted BEAMnrc component module for the Agility MLC.
Overall, the accuracy of iodine and HU values was higher for DLCT than for FKSCT.
The WDI estimated the RED and MD accurately and could form the basis for a new treatment planning approach for pancreatic cancer using contrast-enhancing agent.
